Ziwig
Ziwig is a pioneering company transforming women's health through innovative diagnostics based on salivary RNA analysis and artificial intelligence. Their flagship product, Ziwig Endotest®, is the first in vitro diagnostic medical device for endometriosis using a simple saliva sample, offering reliable results within days. The company combines molecular biology, next-generation sequencing (NGS), and AI to identify RNA signatures linked to diseases, enabling early, non-invasive, and precise diagnosis. Operating an advanced R&D lab at the Institut du Cerveau – Pitié-Salpêtrière and a high-capacity industrial production lab analyzing up to 4500 samples weekly, Ziwig is positioned at the forefront of personalized medicine for women's health. Their approach includes rigorous clinical trials and aims to develop targeted therapies, expanding beyond diagnostics to improve treatment of female pathologies. Ziwig Endotest® is CE marked and will be available in France from 2025 in 100 reference centers, reflecting strong market traction and regulatory compliance.
Ziwig
Ziwig is a pioneering company transforming women's health through innovative diagnostics based on salivary RNA analysis and artificial intelligence. Their flagship product, Ziwig Endotest®, is the first in vitro diagnostic medical device for endometriosis using a simple saliva sample, offering reliable results within days. The company combines molecular biology, next-generation sequencing (NGS), and AI to identify RNA signatures linked to diseases, enabling early, non-invasive, and precise diagnosis. Operating an advanced R&D lab at the Institut du Cerveau – Pitié-Salpêtrière and a high-capacity industrial production lab analyzing up to 4500 samples weekly, Ziwig is positioned at the forefront of personalized medicine for women's health. Their approach includes rigorous clinical trials and aims to develop targeted therapies, expanding beyond diagnostics to improve treatment of female pathologies. Ziwig Endotest® is CE marked and will be available in France from 2025 in 100 reference centers, reflecting strong market traction and regulatory compliance.
TL;DR
Founded: 2020
Headquarters: Lyon, France
Flagship product: Ziwig Endotest® (CE marked saliva-based diagnostic for endometriosis)
Tech: Salivary RNA analysis, NGS, AI; cloud platform / SaaS
Funding: Angel round (Dec 2022); investor listed: Sébastien Breteau
Company Overview
Problem Domain
Women’s health — endometriosis and pelvic health diagnostics/care pathways
Founded
2020
Industry
Biotechnology
Tech Stack
Funding Track Record
Round publicly reported on Dec 1, 2022; amount obfuscated in public profiles
Investor Signal
“Raised an angel round with at least one private investor (Sébastien Breteau)”